Mechanical Valve Divestiture Is Defining Move For MedicalCV’s New CEO
This article was originally published in The Gray Sheet
Executive Summary
MedicalCV will conduct an IDE clinical study to investigate its Atrilaze soft tissue ablation system for cardiac arrhythmias, following an initial 510(k) clearance
You may also be interested in...
MedicalCV AtriLaze
Surgical cardiac tissue ablation system will begin U.S. shipping in January; the firm announced 510(k) clearance Dec. 13. MedicalCV plans a trial for an atrial fibrillation claim (1"The Gray Sheet" Nov. 29, 2004, p. 18)...
MedicalCV AtriLaze
Surgical cardiac tissue ablation system will begin U.S. shipping in January; the firm announced 510(k) clearance Dec. 13. MedicalCV plans a trial for an atrial fibrillation claim (1"The Gray Sheet" Nov. 29, 2004, p. 18)...
St. Jude Builds AF Strategy With $273 Mil. Endocardial Solutions Purchase
St. Jude Medical gains ablation catheter navigation technology to augment its atrial fibrillation portfolio under a $273 mil. acquisition of Endocardial Solutions